Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Drug Use Investigation of EYLEA for Central Retinal Vein Occlusion (CRVO)

Trial Profile

Special Drug Use Investigation of EYLEA for Central Retinal Vein Occlusion (CRVO)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Central retinal vein occlusion
  • Focus Adverse reactions
  • Acronyms JPMS-CRVO
  • Sponsors Bayer
  • Most Recent Events

    • 05 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2016 Planned End Date changed from 1 Nov 2018 to 1 May 2019 as per ClinicalTrails.gov record.
    • 18 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top